A detailed history of Ubs Group Ag transactions in Grifols Sa stock. As of the latest transaction made, Ubs Group Ag holds 942,911 shares of GRFS stock, worth $7.37 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
942,911
Previous 1,061,167 11.14%
Holding current value
$7.37 Million
Previous $6.69 Million 25.25%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.28 - $9.38 $742,647 - $1.11 Million
-118,256 Reduced 11.14%
942,911 $8.37 Million
Q2 2024

Aug 13, 2024

BUY
$6.27 - $7.7 $3.03 Million - $3.72 Million
482,497 Added 83.38%
1,061,167 $6.69 Million
Q1 2024

May 13, 2024

BUY
$5.47 - $11.38 $2.79 Million - $5.8 Million
509,819 Added 740.47%
578,670 $3.87 Million
Q4 2023

Feb 09, 2024

SELL
$7.71 - $11.56 $79,867 - $119,750
-10,359 Reduced 13.08%
68,851 $795,000
Q3 2023

Nov 09, 2023

SELL
$8.91 - $10.91 $126,851 - $155,325
-14,237 Reduced 15.24%
79,210 $723,000
Q2 2023

Aug 11, 2023

SELL
$7.14 - $9.29 $217,784 - $283,363
-30,502 Reduced 24.61%
93,447 $855,000
Q1 2023

May 12, 2023

BUY
$6.65 - $10.69 $392,689 - $631,255
59,051 Added 90.99%
123,949 $913,000
Q4 2022

Feb 08, 2023

SELL
$5.96 - $8.53 $136,114 - $194,808
-22,838 Reduced 26.03%
64,898 $551,000
Q3 2022

Nov 10, 2022

SELL
$5.95 - $14.3 $819,814 - $1.97 Million
-137,784 Reduced 61.1%
87,736 $541,000
Q2 2022

Aug 10, 2022

BUY
$10.6 - $13.28 $590,844 - $740,227
55,740 Added 32.83%
225,520 $2.68 Million
Q1 2022

May 16, 2022

BUY
$10.37 - $12.73 $319,499 - $392,211
30,810 Added 22.17%
169,780 $1.98 Million
Q4 2021

Feb 14, 2022

SELL
$10.21 - $15.27 $795,277 - $1.19 Million
-77,892 Reduced 35.92%
138,970 $1.56 Million
Q3 2021

Nov 15, 2021

BUY
$14.07 - $17.3 $697,365 - $857,457
49,564 Added 29.63%
216,862 $3.17 Million
Q2 2021

Aug 13, 2021

SELL
$16.62 - $18.94 $66.1 Million - $75.4 Million
-3,978,989 Reduced 95.97%
167,298 $2.9 Million
Q1 2021

May 12, 2021

SELL
$15.15 - $19.78 $27.4 Million - $35.8 Million
-1,808,064 Reduced 30.37%
4,146,287 $71.7 Million
Q4 2020

Feb 11, 2021

BUY
$16.86 - $19.67 $70.6 Million - $82.4 Million
4,189,882 Added 237.46%
5,954,351 $110 Million
Q3 2020

Nov 12, 2020

BUY
$15.4 - $20.16 $25.1 Million - $32.8 Million
1,626,881 Added 1182.43%
1,764,469 $30.6 Million
Q2 2020

Jul 31, 2020

BUY
$18.24 - $21.45 $1.73 Million - $2.04 Million
95,041 Added 223.38%
137,588 $2.51 Million
Q1 2020

May 01, 2020

SELL
$16.28 - $25.63 $26.5 Million - $41.7 Million
-1,627,517 Reduced 97.45%
42,547 $857,000
Q4 2019

Feb 14, 2020

SELL
$19.57 - $23.52 $3.4 Million - $4.09 Million
-173,836 Reduced 9.43%
1,670,064 $38.9 Million
Q3 2019

Nov 14, 2019

BUY
$19.85 - $22.76 $10.4 Million - $11.9 Million
521,739 Added 39.46%
1,843,900 $37 Million
Q2 2019

Aug 14, 2019

BUY
$17.59 - $21.1 $4.94 Million - $5.92 Million
280,695 Added 26.95%
1,322,161 $27.9 Million
Q1 2019

May 14, 2019

BUY
$18.01 - $20.11 $1.36 Million - $1.52 Million
75,663 Added 7.83%
1,041,466 $20.9 Million
Q4 2018

Feb 14, 2019

SELL
$17.44 - $21.53 $7.11 Million - $8.78 Million
-407,831 Reduced 29.69%
965,803 $17.7 Million
Q3 2018

Nov 14, 2018

BUY
$19.97 - $21.96 $3.12 Million - $3.43 Million
156,410 Added 12.85%
1,373,634 $29.4 Million
Q2 2018

Aug 14, 2018

BUY
$20.16 - $24.68 $23 Million - $28.1 Million
1,139,980 Added 1475.82%
1,217,224 $26.2 Million
Q1 2018

May 15, 2018

BUY
$20.31 - $24.95 $927,882 - $1.14 Million
45,686 Added 144.77%
77,244 $1.64 Million
Q4 2017

Feb 14, 2018

SELL
$20.99 - $23.89 $7.56 Million - $8.61 Million
-360,378 Reduced 91.95%
31,558 $723,000
Q3 2017

Nov 14, 2017

BUY
$20.07 - $21.89 $7.46 Million - $8.14 Million
371,890 Added 1855.18%
391,936 $8.58 Million
Q2 2017

Aug 14, 2017

SELL
N/A
-165,012 Reduced 89.17%
20,046 $424,000
Q1 2017

Nov 14, 2017

BUY
N/A
185,058
185,058 $3.49 Million

Others Institutions Holding GRFS

About Grifols SA


  • Ticker GRFS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 678,910,976
  • Market Cap $5.31B
  • Description
  • Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...
More about GRFS
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.